Liquid Biopsy is a minimally invasive technique to detect cancer early in dogs and cats, or to make a diagnosis. It may also be used to monitor therapy or to investigate potential relapse. This has become an increasingly high profile development area in veterinary medicine as new techniques become available, especially the detection of biomarkers in the blood or other liquid samples. This lecture will look at what is currently available and how best to access and use these techniques in clinical practice. We will also look at horizon techniques and the use of genomic medicine to make a transformational change in clinical practice. The use of multipack comics, large scale date and liquid biopsy offers a major opportunity to improve cancer outcomes.
Language: English
An application for CE Hours was submitted.
Altavoz:
David Argyle
BVMS PhD DECVIM-CA (Oncology) FRSE FRSA FRCP (Edin) FRCVS
David Argyle is a graduate of Veterinary Medicine and Surgery from the University of Glasgow. He gained his PhD in Immunology and Oncology from the same Faculty. He has served as a clinical academic for the Universities of Glasgow, Wisconsin-Madison and Edinburgh. He is an RCVS and European recognized specialist in veterinary oncology and his major interests are cancer biology, comparative oncology and the development of new theraputics. In 2011 he was appointed William Dick chair of Veterinary Clinical Studies and Dean of Veterinary Medicine at The Royal (Dick) School of Veterinary Studies. In 2022 he was appointed to be Vice Principal and Head of College of Medicine and Veterinary Medicine at the University of Edinburgh. He is a Fellow of the Royal College of Veterinary Surgeons, Fellow of the Royal Society of Edinburgh, Fellow of the Royal College of Physicians (Edinburgh) and a Fellow of the Royal Society for the Encouragement of Arts, Manufactures and Commerce.
